Martı́nB,SmithRJH.C3Glomerulopathy.[Updated2018Apr5].In:AdamMP,ArdingerHH,PagonRA,etal.,editors.GeneReviews®Seat-tle(WA):UniversityofWashington,Seattle;1993-2019.https://www.ncbi.nlm.nih.gov/books/NBK1425/
ComplementFunctionalTesting
Biomarkers&AcquiredDrivers
ofDisease
P
C3Level(ComplementC3PlasmaAssay)
C3cLevel(PlasmaC3cFragmentAssay)
C4Level(PlasmaComplementC4Assay)
FBLevel(PlasmaComplementFactorBAssay)
BaLevel(PlasmaBaFragmentAssay)
BbLevel(PlasmaBbFragmentAssay)
C5Level(ComplementC5Assay)
ProperdinLevel
SolubleC5b‐9Level
FHLevel(PlasmaComplementFactorHAssay)
FILevel(PlasmaComplementFactorIAssay)
Hemolytic‐basedC3NefAssay
MolecularOtolaryngologyandRenalResearchLaboratories
Director:RichardJ.H.Smith,M.D.
Contact:AmyWeaver,ProjectAssistant
Website:https://morl.lab.uiowa.edu
UnderstandingandorderingcomplementtestingforyourpatientswithThromboticMicroangiopathies
ORC3Glomerulopathy
A
B
CH50eqAlternativePathwayFunctionalAssay(APFA)
HemolyticAssayC3b Deposition Assay
NephriticFactors(C3Nef;C5Nef;C4Nef,IFE)
Autoantibodies(FHAA,FBAA)
Inthepast,personsdiagnosedwithcomplement-mediatedkidneydiseaserequiredmultipleteststoattempttoidentifythegeneticcauseoftheirdisease.TheGeneticRenalPanelisacomprehensivetestforpatientswith:
• ThromboticMicroangiopathies(TMAs)
Thromboticthrombocytopenicpurpura(TTP)
Atypicalhemolyticuremicsyndrome(aHUS)
• C3Glomerulopathy
DenseDepositDisease(DDD)
C3Glomerulonephritis(C3GN)
Helping you solve the puzzle of complement-mediated diseases
To order comprehensive testing for your patient please visit our website at:
https://morl.lab.uiowa.edu
TheUniversityofIowaMolecularOtolaryngology&RenalResearchLaboratoriesofferstheComplementFunctionalTesting-apanelofteststhatis:
Comprehensive–testsforcomplementalternativepathwaybiomarkersthatcaninformthestateofthediseaseinavarietyofTMAs,C3Gsandothercomplement-mediatedrenaldiseases.
Easy–patientprovidesonebloodsample.
Fast–onepaneloftestsshortenwaittimeforresults.
Convenient–bloodsampleistakeninlocaldoctor’soffice.
Accurate–99%analyticalspecificity.
Diagnostic–providesadiagnosisandguidetotreatment,transplantationandgeneticcounseling.
Personalized–resultsarediscussedatamultidisciplinarymeetingthatincludesclinicalexperts,scientists,bioinformaticians,humangeneticistsandgeneticcounselors.
Collaborative–MORLwillworkdirectlywithyourphysicianorgeneticcounselortoensurethattestresultsareinterpretedappropriately.
Inexpensiveandef icient–apanelofbiomarkersandfunctionalanalysisversusone biomarker orfunctional test at a time.
Acomprehensiveevaluationofthecomplementsystemrequires three typesofdata tooffer toyour patient the best chance of accuratelyde ining the cause and consequence ofcomplementdysregulation.
ComplementBiomarkerPro iling–Speci icbiomarkersprovideadetailedandmechanisticunderstandingoftheunderlyingcomplementpathologytoaddtodiseasede inition.Byde iningacomplementpathwaysignature,biomarkerscanbeusefultofollowdiseaseactivityand/orseverityintheclinicalsetting.
MeasuringComplementFunction–Measuringandfollowingcomplementactivitycanpredictdiseasestatus(activevs.inactive)andresponsetotherapy.
IdentifyingAcquiredDriversofDisease–IdentifyingacquireddriversofdiseasesuchantibodiestoC3convertase,factorHandfactorBprovidesametrictofollowapatient’sclinicalcourse.
U B
ComplementFunctionaltestingprovidesimportantanswerstomanyquestions.Informationcanbeprovidedonwhetheritistherighttimeforatransplant(whetheratransplantmightbesuccessfulavoidingaquickrecurrence,i.e.kidneyonlyorliver/kidney),andotheradequatemeasurestoconsider.
C3DepositionAssay
N . 2020
